Gribero (Dabigatran Etexilate)

Gribero is prescribed for several anticoagulation indications in adult patients.

• Prevention of stroke and systemic embolism in individuals with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Secondary prevention of recurrent DVT and PE after initial therapy.
• Long‑term anticoagulation in patients at risk of thromboembolic events where warfarin is unsuitable.

Adverse reactions to Gribero vary in frequency and severity.

Common

• Dyspepsia or stomach discomfort.
• Minor gastrointestinal bleeding such as nosebleeds or gum bleeding.
• Nausea or vomiting.
• Headache.

Serious

• Major bleeding events, including intracranial hemorrhage.
• Gastrointestinal perforation or severe ulceration.
• Allergic reactions such as rash or angioedema.
• Elevated liver enzymes indicating possible hepatic injury.

Clinicians should consider several precautions before initiating Gribero therapy.

• Assess renal function, as dosing may need adjustment in impaired kidneys.
• Evaluate bleeding risk, including history of gastrointestinal ulcers or intracranial hemorrhage.
• Use with caution in patients undergoing surgery or invasive procedures.
• Avoid in individuals with active pathological bleeding.
• Counsel women of childbearing potential about unknown pregnancy safety.
• Monitor for signs of thrombotic events if therapy is interrupted.
• Review concomitant use of antiplatelet agents.

Gribero can interact with other medicines, influencing anticoagulant effect or bleeding risk.

Avoid

• Strong P-glycoprotein inhibitors (e.g., ketoconazole, itraconazole, ritonavir) that may increase dabigatran levels.
• Other anticoagulants or antiplatelet drugs (e.g., warfarin, heparin, clopidogrel) when combined without careful monitoring.

Use with caution

• Moderate P-gp inhibitors (e.g., amiodarone, verapamil, quinidine).
• NSAIDs, aspirin, or selective COX‑2 inhibitors that may raise bleeding risk.
• Certain antifungal agents (e.g., fluconazole) and antibiotics (e.g., rifampin) affecting drug transport.
• Herbal supplements such as St. John’s wort that induce P-gp.